Target intelligence / Profile preview

Dihydrolipoyl acetyltransferase (core of pyruvate dehydrogenase complex) (E2 (PDC E2))

Target
E2 (PDC E2)
Molecular classification
Enzyme, Acetyltransferase (specifically dihydrolipoyl acetyltransferase), Multienzyme complex subunit/core protein
01

Overview

The **dihydrolipoyl acetyltransferase (E2)** core is the central catalytic component of the pyruvate dehydrogenase complex (PDC). It organizes and assembles the multi-enzyme complex, shuttles reaction intermediates between active sites via covalently attached lipoyl groups, and catalyzes the transfer of acetyl groups from hydroxyethyl-lipoamide to coenzyme A, forming acetyl-CoA. In mammals, E2 combines with the homologous but pseudocatalytic E3BP to form a dodecahedral or pseudoicosahedral core, serving as the scaffold for integration of the peripheral E1 (pyruvate decarboxylase) and E3 (dihydrolipoamide dehydrogenase) enzymes. This makes E2 central to metabolism and a regulatory node in energy homeostasis.

Other names
Pyruvate dehydrogenase E2 subunitPDH E2Dihydrolipoamide acetyltransferasePDC E2 coreDihydrolipoyl transacetylase
02

Mechanism of action

Activation of pyruvate dehydrogenase via inhibition of pyruvate dehydrogenase kinase increases PDHc activity (e.g., by dichloroacetate) Supplementation of cofactors (thiamine) to support enzymatic function

03

Biological functions

Catalysis of acetyl group transfer to coenzyme A (CoA-SH)Conversion of pyruvate to acetyl-CoACentral metabolic node linking glycolysis to the citric acid cycleOrganization of multienzyme complex and substrate channeling ("swinging arm" shuttling of intermediates via lipoyl domains)
04

Disease associations

Metabolic disorders (e.g., pyruvate dehydrogenase deficiency)Lactic acidosisMitochondrial diseasesCancer (altered PDH activity linked to the Warburg effect)Neurodegenerative diseases (roles in cellular energy supply)
05

Safety considerations

Potential for lactic acidosis if E2 or overall PDHc function is impairedMitochondrial toxicity (if PDHc is pharmacologically inhibited)Risk of impaired energy metabolism leading to organ dysfunction in therapeutic contexts
06

Interacting drugs

Dichloroacetate (DCA; indirectly activates PDC by inhibiting pyruvate dehydrogenase kinase)

2 more in the full profile.

07

Biomarkers

PDC activity level in patient tissue or cellsLipoic acid levelsBlood lactate and pyruvate levels (clinical PDH deficiency diagnosis)

Beyond the preview

Go deeper on Dihydrolipoyl acetyltransferase (core of pyruvate dehydrogenase complex) (E2 (PDC E2)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dihydrolipoyl acetyltransferase (core of pyruvate dehydrogenase complex) (E2 (PDC E2)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call